Clinical Trial Update: MK-2206 for Recurrent Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-2206 for recurrent malignant glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Malignant Glioma | Phase 2 | Status: WITHDRAWN